Potency Assays became an issue because the head honcho Steve Bauer from the FDA was in the middle of some research when MSB were attempting to gain approval. He's has 'developed a high throughput, image-based approach to assess MSC morphology' - sounds like something MSB could make use of
I've posted this before but have a read of the abstract from his published paper that came out shortly after MSB were rebuffed
https://onlinelibrary.wiley.com/doi/abs/10.1002/bit.27974
MSB 2022 - The road to commercialisation, page-1044
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.030(2.18%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.41 | $1.38 | $1.272M | 910.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 19764 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 29848 | 7 |
View Market Depth
| Last trade - 11.02am 17/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |